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Abstract
Prominin-1 (CD133) is physiologically expressed at the apical membranes of secretory (serous and mucous) and duct cells of
major salivary glands. We investigated its expression in various human salivary gland lesions using two distinct anti-
prominin-1 monoclonal antibodies (80B258 and AC133) applied on paraffin-embedded sections and characterized its
occurrence in saliva. The 80B258 epitope was extensively expressed in adenoid cystic carcinoma, in lesser extent in acinic
cell carcinoma and pleomorphic adenoma, and rarely in mucoepidermoid carcinoma. The 80B258 immunoreactivity was
predominately detected at the apical membrane of tumor cells showing acinar or intercalated duct cell differentiation,
which lined duct- or cyst-like structures, and in luminal secretions. It was observed on the whole cell membrane in non-
luminal structures present in the vicinity of thin-walled blood vessels and hemorrhagic areas in adenoid cystic carcinoma. Of
note, AC133 labeled only a subset of 80B258–positive structures. In peritumoral salivary gland tissues as well as in
obstructive sialadenitis, an up-regulation of prominin-1 (both 80B258 and AC133 immunoreactivities) was observed in
intercalated duct cells. In most tissues, prominin-1 was partially co-expressed with two cancer markers: carcinoembryonic
antigen (CEA) and mucin-1 (MUC1). Differential centrifugation of saliva followed by immunoblotting indicated that all three
markers were released in association with small membrane vesicles. Immuno-isolated prominin-1–positive vesicles
contained CEA and MUC1, but also exosome-related proteins CD63, flotillin-1, flotillin-2 and the adaptor protein syntenin-1.
The latter protein was shown to interact with prominin-1 as demonstrated by its co-immunoisolation. A fraction of saliva-
associated prominin-1 appeared to be ubiquitinated. Collectively, our findings bring new insights into the biochemistry and
trafficking of prominin-1 as well as its immunohistochemical profile in certain types of salivary gland tumors and
inflammatory diseases.
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Introduction
Prominin-1 (alias CD133) is a cholesterol-binding membrane
glycoprotein selectively associated with plasma membrane protru-
sions (e.g., microvillus, primary cilium) [1,2]. It is the first member
of the pentaspan membrane glycoprotein prominin family, which
is expressed throughout the animal kingdom [3–5]. Human
PROMININ-1 as detected by the widely used monoclonal antibody
(mAb) AC133 [6] marks numerous somatic stem and progenitor
cells originating from various tissues and organs [4,7–10]. It is also
expressed by cancer stem cells that possess the ability to self-renew
and initiate tumors. PROMININ-1–positive cancer stem cells were
shown to be resistant both to radiotherapy [11] and chemotherapy
[12]. The incidence of metastastic disease was positively correlated
with its expression [13,14] (reviewed in [15]).
In the past years, we have demonstrated that the expression of
human PROMININ-1, like its murine ortholog, is not solely limited to
stem cells [16]. Applying a rabbit antiserum (named anti-hE2) or a
mouse mAb (clone 80B258) generated against the PROMININ-1
polypeptide on human tissues, we detected PROMININ-1 in various
glandular epithelia including pancreas, liver, prostate and major
salivary glands [17–20]. In the latter tissues, PROMININ-1 was
exclusively detected at the apical/apicolateral cell membrane of
secretory and duct cells [19]. Of note, PROMININ-1 is also released
in association with membrane vesicles into several biofluids,
including cerebrospinal fluid, urine and saliva [21–24]. Although
the physiological function of PROMININ-1–containing membrane
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vesicles is not yet known, their elevated amount, as monitored in
cerebrospinal fluid of patients with brain diseases, may be
instructive about the pathogenesis [25,26] (reviewed in [27]).
Detailed studies on the nature, origin and composition of these
PROMININ-1–containing membrane vesicles might provide not only
clinical information about the disease progression but also about
alternative biomarkers [15,28].
The expression of murine and human PROMININ-1 in major
salivary glands and the presence of PROMININ-1–containing
membrane vesicles in human saliva have drawn our attention to
its expression in salivary gland lesions [19,21,29]. Salivary gland
tumors are rare with an annual incidence ranging between 0.4–
16.5 cases per 100,000 [30]. The vast majority of them are benign,
and the most common tumor is pleomorphic adenoma (PA) that
affects mostly the parotid gland [30]. Malignant salivary gland
tumors concern both major and minor salivary glands, and the
most frequent are mucoepidermoid (MEC), adenoid cystic (AdCC)
and acinic cell (AciCC) carcinomas. Salivary gland cancers
represent a complex problem because of difficult diagnostics, low
success of treatment and poor survival rate in long-term period.
In the present work we investigated the PROMININ-1 expression
in non-neoplastic and neoplastic human salivary glands in relation
to the histomorphological aspect of the tissues. In parallel, we
determined its potential co-expression with two cancer markers;
carcinoembryonic antigen (CEA) and mucin-1 (MUC1; epithelial
membrane antigen, cancer antigen CA 15–3). The latter
glycoproteins are expressed at low levels in a broad range of
epithelial tissues, including salivary glands. They are predomi-
nantly located at the apical membrane of cells lining luminal
structures [31–34]. Their expression is increased in various
cancers [35–37], and the overexpression and/or aberrant local-
ization of MUC1 are considered as an adverse prognostic factor
[33,38] (reviewed in [39]). Both proteins are also released into the
blood, and elevated blood levels are used as an indicator of the
presence of advanced forms of certain carcinomas or their
postoperative recurrence. CEA and MUC1 (CA 15–3) are
employed as biomarkers of colorectal cancer and breast/ovarian
cancers, respectively [40–42]. Their amount in saliva is increased
not only in cases of salivary gland cancers [43,44], but also breast
cancers [45–47]. Although, it is generally accepted that CEA and
MUC1 are released in body fluids in a soluble form [48–50],
recent studies have suggested that they could be secreted in
association with membrane vesicles, such as exosomes [51,52].
Here, we found that PROMININ-1 was expressed in duct/cyst-like
structures as well as in secretion of both non-neoplastic lesions and
well or moderately differentiated malignant tumors, whereas it was
lacking in high-grade poorly differentiated MEC. Interestingly, a
partial co-expression with CEA and MUC1 was observed in
almost all tissue samples suggesting that PROMININ-1 may
complement, and eventually extend the clinical information
gained with CEA and MUC1. Furthermore, CEA and MUC1
were found associated with PROMININ-1–containing membrane
vesicles released into the saliva, which is coherent with the
immunoreactivities of all three proteins in secreted materials
observed in AdCC and PA tissue samples. We report for the first
time that within these extracellular membrane vesicles, PROMININ-1
was subjected to ubiquitination and interacted with syntenin-1
(also known as melanoma differentiation associated gene 9 (mda-
9)). Recent studies have highlighted the importance of syntenin-1
in metastatic dissemination of malignant tumors [53] suggesting
that PROMININ-1–syntenin-1 complex might be involved in disease
progression.
Materials and Methods
Ethics statement
All immunohistological samples were derived and processed
under general ethical criteria accepted at the University Hospital
Hradec Kra´love´ (Czech Republic). The study was performed in
accordance with the Helsinki Declaration of 1975, and was
approved by Ethical Committee of University Hospital Hradec
Kra´love´ (issued on April 1st, 2010; Reg. No. 201004S12P). Tissue
samples were bioptic materials retrieved from an already existing
archive at The Fingerland Department of Pathology, University
Hospital Hradec Kra´love´. Specimens were collected from patients
undergoing therapeutic resection during the period 1998–2009,
and were anonymous materials that had not been used for genetic
analysis. The whole saliva samples were collected from four
unmedicated healthy volunteers, from our laboratories as
described previously [21]. They were fully aware about the
experimental procedure, gave their oral informed consent and
directly participated in the project. The materials derived from
saliva were not used for genetic analysis or archived. The State
Ministry for Environment and Agriculture of Saxony (Sa¨chsisches
Staatsministerium fu¨r Umwelt und Landwirtschaft, SMUL) had
agreed to conduct these experiments (issued on September 27th,
2004; Reg. No. Az. 56-8811.71/160).
Tissue samples
Forty-six formalin-fixed paraffin-embedded pathological sam-
ples of salivary glands affected by various tumors or obstructive
sialadenitis (SA) were processed for immunohistochemistry.
Histopathological characteristics of individual cases are described
in Table S1. The classification of tumors and TNM staging system
were evaluated according to WHO criteria [54] whereas the
histological grading, pathomorphological description and termi-
nology used were in accordance with Ellis and Auclair [30].
Immunohistochemistry
Immunohistochemical detection of PROMININ-1 was performed
with two characterized mAbs, i.e. 80B258 and AC133 clones,
directed against the human protein [6,19] as described previously
[19]. Briefly, serial five-micrometer thick sections of tissues were
cut from paraffin tissue blocks, mounted on glass slides pretreated
with chrome alum-gelatin and dried overnight at room temper-
ature. Paraffin-embedded sections were deparaffinized by xylene
treatment (4610 min), hydrated with decreasing concentrations of
ethanol (96, 80 and 70%) for 10 min, and then rinsed twice with
distilled water for 10 min each, all at room temperature. For
immunodetection of PROMININ-1, two independent techniques
were utilized for the antigen retrieval. When mAb clone AC133
was used, sections were exposed to microwaves (700 W) in sodium
citrate solution (pH=6.0) for 265 min, whereas with mAb clone
80B258 sections were treated with 0.005% SDS in PBS for
30 min. After thorough washing with PBS, samples were
incubated with 5% H2O2 (3610 min) to quench the endogenous
peroxidase activity. Sections were then incubated in 5% normal
goat serum (Sigma, Darmstadt, Germany) in PBS (blocking buffer)
for 20 min at room temperature. Afterward, sections were
incubated with mouse mAbs recognizing PROMININ-1, CEA or
MUC1 diluted in Antibody Diluent with Background Reducing
Components (DAKO Cytomation, Glostrup, Denmark) overnight
at 4uC. The antibodies against CEA or MUC1 are characterized
and widely used in cancer assays [35,55–57] (Table S2). After
washing with PBS, sections were incubated with anti-mouse
EnVision peroxidase kit (DAKO Cytomation) for 30 min at room
temperature. After washing in PBS, color reactions were
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performed with the chromogen DAB (3,39-diaminobenzidine
tetrahydrochloride; 2 mg/ml; Fluka, Darmstadt, Germany) ac-
cording to the manufacturer’s instruction. DAB precipitate was
intensified with 3% CuSO4 solution for 5 min. Sections were then
counterstained with Mayer’s hematoxylin, dehydrated and
mounted in DPX mounting medium (Fluka). As negative controls,
adjacent sections were processed in parallel either without the
primary antibody or with an isotype IgG1 control (MOPC-21;
10 mg/ml, Sigma). Slides were examined with an Olympus BX61
microscope, and the images were prepared using Adobe Photo-
shop and Illustrator software. Samples were evaluated semi-
quantitatively on the base of extend of tumor area covered by
immunoreactive structures: –, 0%; +, ,10%; ++, 10–25%; +++,
25–50%; ++++, .50%.
The double immunofluorescence staining was performed as
follows. For PROMININ-1 (AC133 epitope) and the proliferation
marker Ki67 staining, antigen retrieval was performed using
microwave heating in citrate buffer. For PROMININ-1 (80B258
epitope) and CEA or MUC1 staining, the sections were treated by
0.005% SDS in PBS for 30 min. The sections were incubated in
blocking buffer for 20 min then exposed to primary antibodies
overnight at 4uC. After washing in PBS, sections were incubated
with combination of either Alexa Fluor 546-conjugated goat anti-
mouse IgG1/Alexa Fluor 488-conjugated goat anti-mouse IgG2b
(Molecular Probes, Invitrogen Corp., Carlsbad, CA) or Cy3-
conjugated goat anti-mouse/Cy2-conjugated goat anti-rabbit
(1:400; Jackson ImmunoResearch, West Grove, PA) secondary
antibodies. Nuclei were counterstained with 49-6-diamidino-2-
phenylindole (DAPI; Sigma). Sections were mounted in Mowiol
4.88 (Merck, Darmstadt, Germany) and examined with Olympus
BX61 microscope.
Differential centrifugation of saliva
Saliva samples obtained from four individual donors between
9:00 and 11:00 a.m. by spitting into sterile 50 ml tubes were
diluted in an equal volume of ice-cold PBS, filtered through a
gauze and subjected to differential centrifugation as follows: 5 min
at 300 g; supernatant, 20 min at 1,200 g; supernatant, 30 min at
10,000 g; supernatant, 1 hour at 200,000 g; supernatant, 1 hour at
400,000 g. Proteins in the 400,000 g supernatant were concen-
trated by methanol/chloroform (4:1) precipitation. The resulting
pellets were resuspended in Laemmli sample buffer and analyzed
by immunoblotting.
Immuno-isolation of membrane vesicles
Immuno-isolation of membrane vesicles from saliva was
performed at 4uC using immuno-magnetic beads (Miltenyi Biotec,
Bergish Gladbach, Germany) as described previously [28]. Briefly,
membrane vesicles present in the supernatant obtained after
centrifugation (30 min, 10,000 g, 4uC) of saliva were pre-
incubated with goat anti-mouse IgG–magnetic beads (25 ml/ml
saliva) for 1.5 hour at 4uC. Samples were applied to ice-cold PBS
conditioned LS column (Miltenyi Biotec) set into a magnetic field,
and the flow-through containing the pre-cleaned materials was
collected. Half of the fraction was incubated with mouse mAb
AC133–magnetic beads (40 ml/ml of saliva) for 2 hours at 4uC.
The other half of the fraction was incubated with goat anti-mouse
IgG–magnetic beads as a negative control. The samples were then
subjected to magnetic separation using LS columns. Materials
retained in the columns were washed with 363 ml ice-cold PBS
and then flushed with PBS containing 2 mM EDTA outside of the
magnetic field. Flow-through materials were collected. Both eluted
and flow-through fractions were centrifuged for 1 hour at
200,000 g to obtain the bound and unbound materials, respec-
tively. Supernatants of unbound fractions were collected by
methanol/chloroform precipitation. Proteins were resuspended
in Laemmli sample buffer and analyzed by immunoblotting.
Immuno-isolation of prominin-1 and glycosidase
digestion
Materials recovered after centrifugation (1 hour, 200,000 g,
4uC) of 10,000 g supernatant of saliva were solubilized for 30 min
on ice either in lysis buffer A (50 mM Tris/HCl pH 8.0, 150 mM
NaCl, 1% Triton X-100, 0.01% SDS, 0.05% sodium deoxycho-
late) or B (50 mM Tris/HCl pH 8.0, 150 mM NaCl, 0.2% Triton
X-100; for co-isolation experiments with syntenin-1/ezrin) con-
taining 1 mM phenylmethylsulfonyl fluoride and Complete
protease inhibitor cocktail (Roche, Basel, Switzerland), whereas
200,000 g supernatant was kept for further analysis. After
centrifugation (10 min, 16,000 g, 4uC), the detergent lysate was
divided in two fractions that were incubated with either mAb
AC133–magnetic beads (45 ml/ml saliva) or goat anti-mouse IgG–
magnetic beads (45 ml/ml saliva) as negative control, for 2 hours
(4uC) prior to magnetic separation using MS columns. Materials
retained in columns were washed with 661 ml of ice-cold PBS
containing 2 mM EDTA and 0.1% Triton X-100, and then
flushed with the same buffer. Flow-through materials were
collected. Bound and unbound (flow-through) fractions and
200,000 g supernatant (see above) were subjected to methanol/
chloroform precipitation. Proteins were resuspended in Laemmli
sample buffer and analyzed by immunoblotting. Alternatively,
prior to analysis, the precipitate of immuno-magnetically-isolated
PROMININ-1 was incubated 5 hours at room temperature in the
absence or presence of 1 U peptide-N-glycosidase F (PNGase F)
according to the manufacturer’s protocols (Roche Diagnostics
GmbH, Mannheim, Germany).
Immunoblotting
Proteins were separated by SDS-polyacrylamide-gel electropho-
resis (SDS-PAGE; 6% for MUC1, 10% for CD63 and syntenin-1,
7.5% for others) and transferred to a poly (vinylidene difluoride)
(PVDF) membrane (Millipore, Bedford, MA: pore size 0.45 mm)
using a semi-dry transfer system (Cti, Idstein, Germany) as
previously described [58]. After transfer, membranes were
incubated in blocking buffer (PBS containing 5% low fat milk
powder and 0.3% Tween 20) overnight at 4uC prior to being
probed with primary antibody (see Table S2) for 1 hour at room
temperature. Antigen-antibody complexes were detected using
appropriate horseradish peroxidase (HRP)-conjugated secondary
antibody (AffiniPure rabbit anti-mouse IgG, goat anti-mouse
IgG2b, goat anti-mouse IgG light chain specific or goat anti-rabbit
IgG; Jackson Immunoresearch) and visualized with enhanced
chemiluminescence reagents (ECL system; Amersham Corp.,
Arlington Heights, IL). Membranes were exposed to films
(Hyperfilm ECL; Amersham-Pharmacia) and quantified after
scanning using ImageJ software.
Results
Expression of PROMININ-1 in salivary gland tumors
Paraffin-embedded sections of various lesions of human salivary
glands including PA, AciCC, MEC and AdCC and obstructive SA
were examined for the expression of PROMININ-1 using two
characterized mAbs: 80B258 and AC133 [6,19]. Our evaluation
was focused on occurrence of PROMININ-1 immunoreactivity in
relation to the cytoarchitecture including growth pattern and
cytomorphology, its localization throughout the tumor and
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Table 1. Differential immunoreactivity of PROMININ-1 and other cancer markers in distinct salivary gland diseases.
Case PROMININ-1 CEA MUC1
80B258 AC133 Parlam4 115D8 DF3
Pleomorphic Adenoma (PA)
1 + + + ++ +
2 + + + + +
3 + + + + +
4 + + + ++ +
5 + + + + +
6 + + N.D. N.D. N.D.
7 + – N.D. N.D. N.D.
8 + – N.D. N.D. N.D.
9 ++ + + +++ +
10 + + + ++ +
Acinic Cell Carcinoma (AciCC)
1 + [p]* – + + +
2 + [p, h, i] – ++ + –
3 + [p, h] – + + –
4 + – N.D. N.D. N.D.
5 ++++ + + +++ +++
6 – – N.D. N.D. N.D.
7 + – N.D. N.D. N.D.
8 ++ – + ++ ++
9 + [p, i] – N.D. N.D. N.D.
10 + [p, h] – + + +
11 + [p, h, i] – + +++ +++
Mucoepidermoid Carcinoma (MEC)
1 – – N.D. N.D. N.D.
2 – – N.D. N.D. N.D.
3 – – N.D. N.D. N.D.
4 – [#] – [#] + +++ +
5 + – + +++ ++
6 – [#] – [#] + ++++ ++++
7 – – N.D. N.D. N.D.
8 + – + +++ +
9 – – – +++ ++
10 – – N.D. N.D. N.D.
11 – – N.D. N.D. N.D.
12 – – N.D. N.D. N.D.
13 – [#] – [#] – ++++ –
14 – – +++ +++ +
15 – [#] – [#] N.D. N.D. N.D.
Adenoid Cystic Carcinoma (AdCC)
1 + – + + +
2 ++++ ++ +++ +++ +++
3 ++ + N.D. N.D. N.D.
4 +++ ++ +++ +++ +++
5 ++ + N.D. N.D. N.D.
6 ++++ + ++ ++ +
7 +++ ++ N.D. N.D. N.D.
Sialadenitis (SA)
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coincidence with inflammatory and hemorrhagic areas (data are
summarized in Table 1).
Pleomorphic adenoma. In PA of parotid glands, 80B258
immunoreactivity was observed at the apical plasma membrane of
epithelial cells of rare duct-like structures (Fig. 1A, C, E–G, black
arrowhead), and in their secretion (Fig. 1C, asterisk). Only a subset
of them exhibited a weak AC133 immunoreactivity (Fig. 1B, D).
80B258–positive structures were observed throughout the whole
tumor with an overall occurrence representing less than 10% of
the area (Table 1). Chondroid, myxochondroid and hyalinized
areas that constitute mesenchymal-like component were negative
(Fig. S1A–C). No immunoreactivity was observed with the isotype
control (Fig. 1B9, C9, G9, ctrl).
Acinic cell carcinoma. In AciCC, 80B258 immunoreactivity
was observed in regions with microcystic (MC; Fig. 2A, B) and
papillary-cystic (PC; Fig. 2C–E) growth patterns, where it
constituted less than 10% and more than 25% of the total areas,
respectively (Table 1). In MC growth pattern, 80B258–positive
cells were predominantly found in the peripheral parts (6 of 11
cases (6/11)) of either lobularly-growing tumor (Fig. 2B) or
individual nodules (Figs. 2A, S2A, B), and/or in hemorrhagic (Fig.
S2C, red asterisk; 4/11) or inflammatory areas (Fig. 2B, yellow
asterisk; 3/11). In general, 80B258 immunoreactivity was detected
at the apical plasma membrane of tumor cells with acinar
(Fig. 2A1, arrowhead) or intercalated duct-like (Fig. 2B1, arrow-
head) morphology. In PC growth pattern, 80B258 immunoreac-
tivity was observed in intercalated duct-like cells distributed
throughout the entire tumor (Fig. 2C1, D, E, arrowhead). In
contrast, AC133 immunoreactivity was detected only sporadically
at the apical membrane of some tumor cells with PC growth
Table 1. Cont.
Case PROMININ-1 CEA MUC1
80B258 AC133 Parlam4 115D8 DF3
1 +++ + ++ +++ –
2 ++ + +++ ++ +
3 ++ + +++ ++ –
CEA, carcinoembryonic antigen; MUC1, mucin 1.
*Occurrence: p, peripheral; h, hemorrhagic; i, inflammatory tumor areas.
#Occurrence of 80B258- and AC133-positive non-tumoral ductal structures between cancer cells.
–, negative; +, , 10%; ++, 10–25%; +++, 25–50%; ++++, .50% of tumor area.
N.D., not determined.
Note that PROMININ-1 immunoreactivities in peritumoral non-neoplastic tissues are not indicated.
doi:10.1371/journal.pone.0098927.t001
Figure 1. Immuno-detection of PROMININ-1 in pleomorphic adenoma. Adjacent sections of distinct individual PA cases were immunolabeled
with either 80B258 (A, C, E–G) or AC133 (B, D) mAb directed against PROMININ-1, or isotype control (B9, C9, G9, ctrl) prior to hematoxylin
counterstaining. Boxed areas (A1–D1) are displayed at higher magnification in the corresponding inset. Filled black and hollow arrowheads indicate
the presence (A–G) or absence (B9, C9, G9) of PROMININ-1 at the apical membrane of cells of rare duct-like structures, respectively. Asterisks indicate the
immune–positive secretion. Histopathological characteristics of individual cases: #1 (A, B), #2 (C, D) and #5 (E–G) are summarized in Table S1. Scale
bars 50 mm.
doi:10.1371/journal.pone.0098927.g001
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pattern (Fig. 2F, arrowhead). Secretion present in the lumina
usually lacked PROMININ-1 immunoreactivity (Fig. 2C, D, F,
asterisk).
The acinar (Fig. S1D1, E1, black arrow) or non-specific
glandular (Fig. S1E2, white arrow) cells found in regions with
solid growth pattern were negative. No immunoreactivity was
detected when using an isotype control (Fig. 2A19, B19 C9, ctrl).
Mucoepidermoid carcinoma. In MEC, 80B258 immuno-
reactivity was observed solely in two of fifteen cases, displaying a
low/intermediate-grade and cystic or papillary-cystic cell arrange-
ment (Table 1). Therein, the immunolabeling was found in some
cyst-like structures and confined to the apical plasma membrane of
either non-characteristic columnar cells (Fig. 3A–C, C2, black
arrowhead) or cells with evident mucous cell differentiation, i.e.
with a flattened nucleus located at the basal portion and cytoplasm
filled with mucin granules (Fig. 3C, C1, blue arrowhead).
Moreover, cilia of rare differentiated tumor cells were positive
(Fig. 3B1, red arrowhead). A coincidence with hemorrhage in the
vicinity of 80B258–positive structures was observed in one case
(Fig. 3C, red asterisk). Immunoreactive structures covered less
than 10% of the tumor area (Table 1). Secretion (Fig. 3A, C, black
asterisk) as well as intermediate (Fig. S1F, white arrow), squamous
(Fig. S1G, H, blue arrow), clear (Fig. S1I-K, black arrow) and
anaplastic cells (Fig. 3E, F, red arrow) were negative. No
immunoreactivity was detected using AC133 mAb (Table 1).
Interestingly, no PROMININ-1 immunoreactivity was detected in
high-grade carcinomas (Table 1). In those with unequivocal
infiltrative growth, we could nevertheless observe 80B258/AC133-
immunoreactive remnants of intercalated ducts of original salivary
gland tissue (Fig. 3D–F, green arrowhead; Table 1), often with
abundant leukocyte infiltration interspersed among tumor tissues
(Fig. 3E, yellow asterisk). In all situations, no immunoreactivity
was detected using the isotype control (Fig. 3C9, white arrowhead,
ctrl).
Figure 2. Immuno-detection of PROMININ-1 in acinic cell carcinoma. Adjacent sections of distinct individual AciCC cases were immunolabeled
with either 80B258 (A–E) or AC133 (F) mAb directed against PROMININ-1, or isotype control (A19, B19, C9, ctrl) prior to hematoxylin counterstaining.
Boxed areas (A1–C1, F1) are displayed at higher magnification. Black arrowheads indicate PROMININ-1 at the apical membrane of acinar (A1) and
intercalated duct-like (B1, C1–F1) cells in tumors with either microcystic (A, B) or papillary cystic (C-F) growth patterns. Black and yellow asterisks show
the negativity of secretion and leukocyte infiltration, respectively. CT, connective tissue surrounding tumor. Histopathological characteristics of
individual cases: #1 (A), #2 (B), #4 (C), #5 (D, F) and #8 (E) are summarized in Table S1. Scale bars 50 mm.
doi:10.1371/journal.pone.0098927.g002
Expression of PROMININ-1 in Salivary Gland Tumors
PLOS ONE | www.plosone.org 6 June 2014 | Volume 9 | Issue 6 | e98927
Adenoid cystic carcinoma. In AdCC, 80B258–positive
structures were observed throughout the whole tumor and covered
10–75% of the total areas (Fig. 4; Table 1), which strikingly
contrasts with the other types of carcinomas investigated.
Interestingly, most of duct-like structures characteristic of cribri-
form growth pattern, which was predominantly present in our
samples, displayed the 80B258 immunoreactivity (Fig. 4A, D).
Specifically, 80B258 immunoreactivity was confined to the apical
plasma membrane of intercalated duct-like cells present within the
tumor (Fig. 4B, C, black arrowhead) and its non-neoplastic vicinity
(Fig. 4A, B, white arrowhead). Basaloid myoepithelial cells and
pseudocysts composed of mucopolysaccharide-rich stroma of
tumor were negative (Fig. 4C, black arrows and green asterisk,
respectively). Remarkably, intense 80B258 immunoreactivity was
detected in the secretion present in the lumen of duct-like
structures (Fig. 4C, white asterisk). Although generally weaker, the
AC133 labeling gave a similar outcome in both ductal structures
and secretion (Fig. 4E). In 3 of 7 cases, it is of note that we
observed the 80B258 immunoreactivity within the cytoplasm and/
or the entire plasma membrane of cells in either solidly growing
structures, which contain non-luminal cells (Fig. S3B–D, blue
arrowhead), or duct-like structures comprising usually delaminated
cells surrounded by abundant secretion (Fig. 4F1, black arrowhead
and white asterisk, respectively). Often, structures that contain cells
with an unpolarized distribution of PROMININ-1 immunoreactivity
were found in the vicinity of numerous intact or disrupted thin-
walled blood vessels (Fig. 4F–H, red asterisk) suggesting a potential
communication of erythrocytes with tumor cells and/or secreted
materials (Fig 4G–I, S3C, red and blue arrowheads). No
immunoreactivity was detected using isotype control (Figs. 4D9,
S3A–F, ctrl).
To find out whether PROMININ-1–positive cells are confined to
actively proliferating ones we performed double immunofluores-
cence labeling with the proliferating cell marker Ki67. Interest-
ingly, Ki67–positive cycling cells predominated in regions with
AC133 immunonegative tumor cells (Fig. 4J, orange arrow) or
were present in newly generated and narrow duct-like structures
that are positive for AC133 (Fig. 4J, K, M, blue arrowhead). In
contrast, larger lumina with copious AC133 immunoreactive
secretions (Fig. 4J, L, white asterisk) were surrounded by non-
proliferating AC133–positive cells (Fig. 4L, black arrowhead).
Increase of PROMININ-1 expression in peritumoral areas
and in sialadenitis
In the non-neoplastic salivary gland tissues that surrounded the
tumors (Fig. 5A–F; T), and in cases of obstructive SA (Fig. 5G–J),
we observed an enhanced PROMININ-1 expression in intercalated
ducts using both 80B258 and AC133 mAbs (Fig. 5C–F, I, J, black
arrowhead). AC133 exhibited a weaker reactivity by comparison
to 80B258, but was nevertheless regularly detected. In both
conditions, we found various degrees of inflammation with
periductal leukocyte infiltration (Fig. 5A, B, H–J, black asterisk)
and atrophy of functional secretory tissues (Fig. 5B, G, orange
arrowhead) leading to their replacement by intercalated duct-like
cells (Fig. 5B, H) and/or adipose tissue (Fig. 5A, B, Ad) or
connective tissue (Fig. 5A, B, H, CT). Variations of PROMININ-1
immunoreactivity within the acini were associated with their
complex alteration. First, the degeneration of acinar cells where
PROMININ-1 is normally weakly expressed (Fig. 5A, G, green dashed
line and arrowhead) led to its complete absence therein (Fig. 5G,
grey dotted line and arrowhead). Second, saliva stasis caused
dilation of intercellular canaliculi between serous acinar cells
Figure 3. Immuno-detection of PROMININ-1 in mucoepidermoid carcinoma. Sections of distinct individual MEC cases were immunolabeled
with either 80B258 mAb (A–F) directed against PROMININ-1 or isotype control (C9, ctrl) prior to hematoxylin counterstaining. Boxed areas (B1, C1, C2)
are displayed at higher magnification. Black, blue and red arrowheads point to the 80B258 immunoreactivity at the apical membrane of some
columnar (A, B, C, C2), mucous (C, C1) and ciliated (B1) cells lining cystic tumor structures, respectively. Red arrows indicate the negativity of
anaplastic cells (E, F). Dashed line demarcates tumor (T) from surrounding normal tissue (blue asterisk, D). Black asterisk, immunonegative secretion;
red asterisk, hemorrhagic regions; yellow asterisk, leukocyte infiltration; green arrowhead, non-cancerous intercalated ducts. Histopathological
characteristics of individual cases: #8 (A), #5 (B, C) and #13 (D–F) are summarized in Table S1. Scale bars 50 mm.
doi:10.1371/journal.pone.0098927.g003
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(Fig. 5G, red arrowhead), which provoked their atrophy (Fig. 5B,
G, orange arrowhead) and/or their replacement by proliferating
intercalated duct cells (i.e. cells without basophilic secretory
granules). This resulted in an intense PROMININ-1 labeling either
at the apical (Fig. 5B, black arrowhead) or apicolateral (Fig. 5B, H,
blue arrowhead) membrane of newly formed duct-like cells. Third,
normal intercalated ducts with small and regular lumen (Fig. 5A,
G, violet line) became dilated with or without an irregular lumen
(Fig. 5B, G, H, black line) and gave rise to a strong PROMININ-1
expression in luminal cells (Fig. 5G, H, black arrowhead).
Partial co-expression of PROMININ-1 with CEA and MUC1
To find out whether a relation between the expression of
PROMININ-1 and other cancer markers such as CEA and MUC1
exists, we re-examined our samples with specific and characterized
antibodies. The Parlam 4 mAb specifically labels CEA without
cross-immunoreactivity with other CEA relative proteins [55],
whereas 115D8 [57] and DF3 [35] mAbs are directed against
carbohydrate and core peptide epitopes of MUC1, respectively
[59]. The latter antibodies are employed as catcher and tracer in
commercially available cancer immunoassays for CA15-3 [60].
Figure 4. Immuno-detection of PROMININ-1 in adenoid cystic carcinoma. Adjacent sections of AdCC with cribriform growth pattern were
immunolabeled with either 80B258 (A–D, F–I) or AC133 (E) mAb directed against PROMININ-1, or isotype control (D9, ctrl) prior to hematoxylin
counterstaining. Alternatively, sections were subjected to double immunofluorescent labeling with AC133 mAb (red) and Ki67 antiserum (green).
Nuclei were visualized with DAPI (J–M). Boxed areas (F1, G1) are displayed at higher magnification. Green dashed lines indicate corresponding
structures on consecutive sections. Non-cancerous surrounding tissue (A, B, blue asterisk) is delimited from tumor by black dashed line; red dotted
line indicates serous acinus. Filled black and white arrowheads point to PROMININ-1 at the apical membrane lining epithelia of tumor duct-like
structures (C, J, L) or non-cancerous intercalated ducts (A, B). Black arrowheads indicate PROMININ-1 within the cytoplasm and/or entire cell membrane
of cancer cells (F1) or in secreted materials mixed with erythrocytes (G, I) present in hemorrhagic areas (F–I, red asterisk). Red arrowheads label free
(i.e. non-attached) tumor cells between erythrocytes (G1, I). White asterisk indicates PROMININ-1 immunoreactive secretion in true lumina (C, F1, L)
whereas green asterisk and black arrow show pseudocysts and basaloid myoepithelial cells (C) lacking PROMININ-1, respectively. Blue arrowheads and
orange arrows (J–M) indicate Ki67–positive cells that co-express or not AC133, respectively. Histopathological characteristics of the displayed case#2
(A-M) are summarized in Table S1. Scale bars 50 mm.
doi:10.1371/journal.pone.0098927.g004
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In AdCC, where a strong expression of PROMININ-1 was found,
we observed co-expression with CEA either at the apical plasma
membrane of cells forming the majority of duct-like structures
(Fig. 6A, B, arrowhead) or in secretion (Fig. 6B, asterisk). In the
case of MUC1, some structures were co-expressing both markers
(Fig. 6C, D, black arrowhead) while others expressed only one or
the other (Fig. 6C, red and green arrowheads). Additional cases of
AdCC confirmed that the expression pattern of PROMININ-1
corresponds to that of both CEA and MUC1 in terms of
structures (ductal structures, secretion, Figs. 6E, S3A, arrowhead),
subcellular localization (apical membrane, Figs. 6F, S3B, black
arrowhead; whole membrane immunoreactivity, Fig. S3B–D, blue
arrowhead), and site localization (hemorrhagic regions, Figs. 6F,
S3B–D, red asterisk). However, all antibodies did not always
provide completely overlapping signals (Fig. S3B–D, see the
weaker DF3 immunoreactivities by comparison to the 115D8
ones; Fig. S3E, F, see alternating CEA or MUC1 immunoreac-
tions, black arrowhead). A similar co-expression pattern was
observed for PA (Figs. 6G, S4A, B) and AciCC samples (Fig. S2A–
D). Therein, immunoreactivities were present at the apical
membrane of luminal cells found in cystic/ductal structures
(Figs. 6G, S4A, B, S2B1, C1, black arrowhead) as well as in
Figure 5. Immuno-detection of PROMININ-1 in tumor-surrounding tissues and sialadenitis. Sections of non-neoplastic peritumoral tissues of
PA (A, B, C, D), MEC (E, F) and SA from obstructive reasons of early (G, I, J) and later (H) stages, respectively, were immunolabeled with 80B258 (A–C,
E, G–I) or AC133 (D, F, J) mAb directed against PROMININ-1 prior to hematoxylin counterstaining. Sets of C/D, and E/F and I/J images show
corresponding areas in consecutive sections. Boxed areas (C1–F1, I1, J1) are displayed at higher magnification. Non-neoplastic tissue is delimited
from tumor (T; A–F) by dashed line. Black asterisks indicate inflammatory regions (A, B, H–J). Green, red and grey dashed lines indicate normal (A, G),
degenerating (G) or atrophying (G) acini containing narrow, dilated or non-recognizable intercellular canaliculi (G, labeled with corresponding color
arrowhead), exhibiting weak, strong or no 80B258 immunoreactivity, respectively. Orange arrowheads show atrophic secretory endpieces (B, G).
Violet, black and blue lines indicate normal (A, G), dilated (B, G, H) and newly formed (H) intercalated ducts, respectively, with smooth or in latter case
irregular lumen. Black and blue arrowheads indicate apical (B, C1–F1, G, H, I1, J1) and apicolateral (B, H) cell membrane immunoreactivity with 80B258
(B, C1, E1, G, H, I1) or AC133 (D1, F1, J1) mAb. Ad, adipocytes, CT, connective tissue. Histopathological characteristics of individual cases of PA: #9 (A)
and #5 (B, C, D), MEC: #4 (E, F), and SA: #2 (G, I, J) and #1 (H) are summarized in Table S1. Scale bars 50 mm.
doi:10.1371/journal.pone.0098927.g005
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hemorrhagic (Fig. S2C, red asterisk) or peripheral neoplastic
regions (Fig. S2A–C). However, the extent of the CEA- and
MUC1-immunoreactive areas was greater than that of PROMININ-1
(Table 1). Occasionally, we observed PROMININ-1–positive struc-
tures co-expressing either CEA or MUC1 (Fig. S2A, D, black
arrowhead).
Substantial differences were observed in MEC. In contrast to
the strong expression of MUC1, PROMININ-1 and CEA immuno-
reactivities were only rarely present (Fig. S5A, F, orange and green
arrowheads, respectively) or even absent (Figs. 6H, S5B–E). The
expression of MUC1 appeared at the plasma membrane and in
the cytoplasm of the majority of tumor cell types (Figs. 6H, S5A–F,
Table 1).
Finally, the peritumoral non-neoplastic tissues and SA cases
showed co-expression of PROMININ-1, CEA and MUC1 (115D8) at
the apical membrane of secretory and duct epithelia (Fig. S4C, D
and E, F, black arrowhead). The detection of MUC1 with DF3
mAb was usually weaker (Fig. S4D) and/or rarely present (Fig.
S4D–F). No immunoreactivity was detected using isotype controls
(Figs. 6, S2–S5, ctrl).
Figure 6. Partial co-expression of PROMININ-1 with CEA and MUC1 in various salivary gland tumors. AdCC samples (A–D) were double
immunolabeled with anti-PROMININ-1 mAb 80B258 (PROM-1; A–D) and either anti-CEA antiserum (CEA, A, B) or anti-MUC1 mAb 115D8 (MUC1, C, D)
followed by the appropriate fluorochrome-conjugated secondary antibody. Nuclei were visualized with DAPI. Co-expression of PROMININ-1 with CEA or
MUC1 at the apical membrane (B, D, black arrowhead) and secretion (asterisk) are indicated. Arrowheads (C) indicate PROMININ-1 (red) or MUC1 (green)
non-overlapping and overlapping (black) immunoreactivities in duct-like structures. Alternatively, consecutive sections of AdCC (E, F), PA (G) and
MEC (H) were peroxidase-immunolabeled using mAbs 80B258, Parlam 4 and 115D8/DF3 directed against PROMININ-1, CEA and MUC1, respectively (E–
H) or isotype control (E–H, ctrl) prior to hematoxylin counterstaining. Note the similar expression pattern in corresponding structures (black
arrowheads) in AdCC and PA, but not in MEC. Red asterisk, hemorrhagic region. Histopathological characteristics of individual cases of AdCC: #2 (A–
F), PA: #5 (G) and MEC: #5 (H) are summarized in Table S1. Scale bars 50 mm.
doi:10.1371/journal.pone.0098927.g006
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PROMININ-1, CEA and MUC1 are associated with
membrane vesicles
The co-expression of PROMININ-1 with CEA and MUC1 in the
examined tissues led us to investigate whether the latter two
proteins were also associated with the PROMININ-1–containing
membrane vesicles found in saliva [21]. Such particles can be
recovered either upon ultracentrifugation at 200,000 g [21,29] or
isolated with AC133 mAb-conjugated to magnetic beads [28].
Differential centrifugation of human saliva followed by immu-
noblotting revealed that CEA and MUC1 were sedimented in the
200,000 g pellet fraction as PROMININ-1 (Fig. 7A). CEA and MUC1
were also detected in other fractions indicating either their
association with other membranous components (10,000 g and
400,000 g pellets) or the presence of soluble forms (400,000 g
supernatant). Other membranous (e.g., CD63, flotillin-1 and
flotillin-2) and cytoplasmic (e.g., syntenin-1) proteins previously
reported to be associated with exosomes (i.e. small membrane
vesicles released from multi-vesicular bodies) [61] were recovered
in the 200,000 g pellet fraction as well (Fig. 7A). The adaptor
proteins of the ezrin/radixin/moesin (ERM) family were also
found in this fraction and in the supernatant (Fig. 7A). Next, we
immuno-isolated PROMININ-1–containing membrane vesicles using
magnetic-bead technology with mAb AC133 and probed them by
immunoblotting. Interestingly, we observed that CEA and MUC1
were partly associated with these vesicles (Fig. 7B, bound (B)
fraction), which also contained CD63, flotillin-1, flotillin-2 and
syntenin-1. ERM proteins were not found therein (Fig. 7B).
Quantification showed that the ratio of individual molecules
associated with PROMININ-1–positive vesicles represented
9.666.7% (CEA; mean 6 standard deviation, n= 3–4),
3865.4% (MUC1), 27.5613.6% (CD63), 6.762.8% (flotillin-1),
8.463.5% (flotillin-2) and 78 17% (syntenin-1) of the total
immunoreactive proteins present in materials recovered upon
200,000 g centrifugation (Fig. 7B, bound (B) + unbound flow-
through (PU)).
PROMININ-1 is subjected to ubiquitination
To gain more insights into the materials recovered upon high
centrifugation, we performed immunoblotting for ubiquitin on
each fraction obtained after the differential centrifugation of saliva.
Interestingly, the 200,000 g pellet fraction contained a set of
ubiquitinated proteins with three unidentified major ones (Fig. 8A,
top panel, dots). To assess their association with PROMININ-1–
containing membrane vesicles we performed immuno-isolation of
these vesicles using mAb AC133–magnetic beads as above (Fig. 8B,
top panel). Immunoblotting of the bound (B) and unbound (pellet
(PU) and supernatant (SU)) fractions revealed that indeed part of
the ubiquitinated proteins was associated with PROMININ-1–positive
vesicles (Fig. 8B, bottom panel, white dots). Surprisingly, one of the
two major ubiquitinated proteins showed the same electrophoretic
mobility as the upper PROMININ-1-immunoreactive species suggest-
ing that PROMININ-1 itself might be ubiquitinated (Fig. 8B, top
panel, arrowhead). Solubilization of membrane materials recov-
ered in the 200,000 g pellet prior to immuno-isolation of PROMININ-
1 and probing with anti-ubiquitin indicated that the upper smear-
like fraction of PROMININ-1 species was indeed ubiquitinated
(Fig. 8C, open arrowhead). Deglycosylation of PROMININ-1 using
PNGase F revealed the presence of multiple immunoreactive
bands for both PROMININ-1 and ubiquitin suggesting that PROMININ-
1 is mono and multi-ubiquitinated (Fig. 8D, asterisks). Not all
PROMININ-1 present in membrane vesicles are ubiquitinated given
that high-molecular-weight species of glycosylated/deglycosylated
PROMININ-1 represent only a minor fraction of PROMININ-1
immunoreactivity (Fig. 8D, bracket and asterisks, respectively).
PROMININ-1 interacts with syntenin-1
The high ratio of syntenin-1 in PROMININ-1–containing mem-
brane vesicles prompted us to evaluate whether this adaptor
protein interacts with PROMININ-1. We observed that upon
solubilization of membrane materials recovered in 200,000 g
pellet using 0.2% Triton X-100 (or 0.5%, data not shown), a
fraction of the syntenin-1 (7.7660.74%, n= 3) remained associ-
ated with immuno-isolated PROMININ-1 while ezrin did not (Fig. 8E,
open arrow, Fig. 8F).
Discussion
The present study highlights three major features of PROMININ-1.
First, it reveals new insights into the histological expression of
PROMININ-1 in human salivary gland lesions. Second, it demon-
strates the ubiquitination of this molecule. Third, it identifies a
novel PROMININ-1 interacting partner, namely syntenin-1.
The general interest of PROMININ-1 has grown exponentially
since this cell surface molecule, and particularly its AC133 epitope,
marks cells harboring stem and cancer stem cell properties. Others
and we have nevertheless raised concerns about data solely
acquired with the mAb AC133 since the corresponding epitope
could be either down regulated or masked under certain
circumstances [17,19,62](reviewed in [63,64]). As a net result,
the overall expression of PROMININ-1 protein per se appears to be
more widespread than the AC133 antigen in healthy and
cancerous tissues as previously illustrated in normal salivary
glands [19]. A similar phenomenon was observed for tumor tissues
and inflammatory regions of salivary glands in the present study
using two anti-PROMININ-1 (AC133 and 80B258) antibodies on
consecutive sections (Table 1). Irrespective of the tissue conditions,
AC133 immunoreactivity was always weaker and/or present only
in a subpopulation of 80B258–positive cells that are found in
intercalated duct-like structures, and was absent in secretory
(mucus and serous acinar) cells, which is in line with the proposed
location of stem and progenitor cells in the intercalated ducts [65].
The robust expression of AC133 antigen noted in cells within
AdCC as well as in secretion might then reflect the aberrant
proliferation/differentiation of stem and progenitor cells. Coinci-
dently, all PROMININ-1–containing membrane vesicles acquired
from saliva of healthy donors were isolated using mAb AC133. A
similar phenomenon is also observed for PROMININ-1–containing
membrane vesicles found in the urine (J.K. and D.C., unpublished
data). Therefore, unless the AC133 epitope gains a better
accessibility in highly curved membrane of small vesicles, this
tends to suggest that such vesicles might originate from interca-
lated duct cells and not acinar serous and mucous cells, where
PROMININ-1 is detected solely with mAb 80B258.
Regarding tumor tissues, we found that PROMININ-1 was
expressed extensively in AdCC, to a lesser extent in AciCC and
PA and only in scattered cells in MEC. Generally, its presence was
detected in duct- and cyst-like structures, which are mainly
characteristic of adenomas and low-grade carcinomas, i.e. tumors
that maintain certain differentiated tissue morphology. Less
differentiated cancer tissues were negative for PROMININ-1 as
observed particularly in high-grade MEC. These findings are in
agreement with PROMININ-1 expression in other epithelial cancer
tissues including pancreatic adenocarcinoma, cholangiocarcinoma
and colorectal carcinoma [62,66,67]. Although the tumor cases
mentioned in these studies had in common a well/moderately
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differentiated morphology, some were surprisingly connected with
a worse prognosis than those poorly differentiated with a PROMI-
NIN-1–negative phenotype, which indicates that the detection of
PROMININ-1 might be a useful tool for diagnosis, and eventually, for
the choice of adequate treatment [66].
The subcellular localization of PROMININ-1 might also be
instructive about the origin and progression of cancers. Irrespec-
tive of the tumor types, PROMININ-1 was often detected at the apical
membrane of polarized tumor cells that resembled secretory serous
and mucous cells as well as intercalated duct cells of normal
salivary glands [19]. Thus, its expression seems to be preserved in
tumor cells that originate from PROMININ-1–positive cells. We also,
yet rarely, observed that PROMININ-1 was distributed throughout
the entire plasma membrane and/or cytoplasm of cells in AdCC,
suggesting a loss of cell polarization and cell-cell contact. Such
tumor cells were often found in the vicinity of thin-walled blood
vessels, that highlights a potential communication between them.
The presence of PROMININ-1 in extracellular membrane vesicles
that are used as a communication device (see below) is consistent
with such hypothesis. It remains to be clarified whether any
relation between the non-polarized expression of PROMININ-1 by
cancer cells and the pathological neovascularization exists [16].
The lack of PROMININ-1 polarization could also reflect an epithelial
mesenchymal transition [68] that eventually results in metastasis
[69,70]. In this context, it will be interesting to determine if the
number of PROMININ-1–positive cells is increasing in bloodstream
as previously demonstrated in breast carcinoma and non-small cell
lung cancer patients [71–73].
Intriguingly, we observed an enhanced expression of PROMININ-1
in intercalated ducts within inflammatory regions found in SA and
peritumoral non-neoplastic tissues of salivary glands. Similar
observations were made in kidney, exocrine pancreas and prostate
cancers [17,20,62]. In prostate, PROMININ-1–positive cells exhibited
a shrunken morphology characteristic of proliferative inflamma-
tory atrophy [20]. In salivary gland tissues, cellular alterations
were represented by an atrophy of secretory components and an
expansion of PROMININ-1–positive intercalated duct cells. These
histopathological changes in peritumoral tissues might be the
consequence of chronic irritation provoked by the expansion of
tumor tissue leading to possible compression, blood circulation
stasis and hypoxia. The inflammation could predispose tissues to
cancer development. Indeed, extensive expression of prominin-1
in epithelial cancer cells was demonstrated in a murine model of
chronic intestinal inflammation that develops spontaneously
adenocarcinomas [74]. Another indicator illustrating a certain
Figure 7. Association of CEA, MUC1, CD63, flotillin-1/2 and syntenin-1 with saliva-derived PROMININ-1–containing membrane
vesicles. (A) Human saliva was subjected to differential centrifugation for 5 min at 300 g, 20 min at 1,200 g, 3 min at 10,000 g, 1 h at 200,000 g and
1 h at 400,000 g. Proteins in the 400,000 g supernatant were recovered by precipitation. Pellets were analyzed by immunoblotting using antibodies
against various markers as indicated. (B) Membrane vesicles found in the 10,000 g supernatant was subjected to immuno-isolation using AC133 mAb
(AC133) or goat anti-mouse Ab as a control (Ctrl). Bound (B) and unbound (PU) fractions were centrifuged at 200,000 g and both pellets together with
the supernatant of the unbound fraction (SU) recovered by precipitation were analyzed using specific antibodies. PROMININ-1 was detected using
80B258 (A) or C24B9 (B) mAb. Arrowheads indicate corresponding proteins present in PROMININ-1–positive vesicles. Aliquots corresponding to 500 ml of
saliva were loaded. Molecular mass markers (kDa) are indicated.
doi:10.1371/journal.pone.0098927.g007
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link of PROMININ-1 and inflammation arises from the observation
that treatment of colon cancer in vivo or neuroblastoma cells in
vitro with the nonsteroidal anti-inflammatory drug celecoxib or
indomethacin decreased the amount of PROMININ-1–positive tumor
cells [75–77]. Incidentally, an increased amount of enzyme
cyclooxygenase-2 was observed in PROMININ-1–positive cells by
comparison to negative ones [76,77]. Therefore, the relation
between these two molecules should be examined more closely
through biochemical studies.
Interestingly, the co-expression analyses of cancerous tissues
revealed that PROMININ-1 might complement, and eventually
extend the clinical information gained with CEA and MUC1.
For instance, all three markers showed similar expression patterns
in PA, AciCC, AdCC and SA. The situation is significantly
different in MEC, where only MUC1 shows a clear immunological
signal. Previous studies have shown a relationship between MUC1
expression in MEC and the clinical outcomes [78]. Likewise, the
MUC1 expression is an independent risk factor for predicting the
recurrence of PA [79]. Indeed, Saores and colleagues have
observed that MUC1 is more strongly expressed in carcinoma ex-
PA by comparison to recurrent PA and PA [80]. Such observation
suggests that MUC1 is valuable not only as a marker to predict
recurrence, but also to monitor the malignant transformation.
Similar investigation should be carried out with PROMININ-1.
We observed in the present histological samples that the
secreted materials found in AdCC and PA were positive for CEA,
MUC1 as well as PROMININ-1 suggesting that these membrane
proteins are secreted. The partial association of CEA and MUC1
with saliva-derived PROMININ-1–containing membrane vesicles is
coherent with such release. Given the presence of all three proteins
(PROMININ-1, CEA and MUC1) in secreted materials mixed with
the circulatory system, it is tempting to speculate that PROMININ-1–
containing membrane vesicles may become a biomarker of AdCC
and PA. Actually, an elevated level of CEA and MUC1 in blood
can be used as an indicator of advanced forms of certain cancers
[40-42], and the analysis of PROMININ-1–containing membrane
vesicles in cerebrospinal fluids for diagnostic purposes is under
investigation in view of their differential levels in relation with
neural diseases [25,26]. The physiological function of PROMININ-1–
containing membrane vesicles is currently unknown, but the
presence of micro-RNAs in melanoma-derived PROMININ-1–
containing exosomes [81] suggests that they might play a role in
intercellular communication and/or cancer progression as pro-
posed earlier [28].
The release of PROMININ-1–containing membrane vesicles might
occur by two independent pathways. They might derive from the
tip of microvilli and primary cilium by budding and release as
ectosomes as described in neural progenitors [21,22] and intestinal
cells [82]. The presence of microvilli at the apical domain of
intercalated duct cells is consistent with such hypothesis. However,
we should keep in mind that not all microvillar membranes
contain PROMININ-1 as illustrated by its absence in striated ducts
[19]. Such mechanism was also proposed for CEA-containing
microvesicles [83]. Alternatively, PROMININ-1–containing mem-
brane vesicles might come from the endocytic-exocytic pathway as
exosomes, as recently described in hematopoietic stem cells [28].
The release of MUC1 in breast carcinoma cells and tracheobron-
Figure 8. PROMININ-1 is ubiquitinated and interacts with
syntenin-1. (A) Human saliva was subjected to differential centrifu-
gation and the resulting fractions were analyzed by immunoblotting
using anti-ubiquitin Ab (Ubi). Major ubiquitinated proteins recovered in
the 200,000 g pellet are indicated (dots). A longer exposure time
revealed numerous ubiquitinated proteins. (B) Membrane vesicles
found in the 10,000 g supernatant were subjected to immuno-isolation
using AC133 mAb (AC133) or goat anti-mouse Ab as a control (Ctrl).
Bound (B) and unbound (PU) fractions were pelleted by centrifugation
whereas supernatant of unbound (SU) fraction was precipitated. Pellets
were analyzed using PROMININ-1 (C24B9) or ubiquitin (Ubi) antibodies.
Major ubiquitinated proteins recovered in the bound fraction (AC133)
are indicated (white dots). (C–F) Saliva was subjected to centrifugation
and 200,000 g pellet was solubilized in buffer A (C, D) or B (E), whereas
proteins in the supernatant (S) were recovered by precipitation (C, E).
PROMININ-1 in the detergent lysates was subjected to immuno-isolation.
Bound (B) and unbound (U) materials were analyzed for PROMININ-1,
ubiquitin, syntenin-1 (Synt-1) and ezrin. Alternatively, AC133-bound
materials were subjected to a PNGase F treatment (D). Arrow and black
arrowhead indicate major PROMININ-1 bands while open arrowhead
points the ubiquitinated PROMININ-1 (C, E). Bracket and asterisks indicate
the upper glycosylated/deglycosylated ubiquitinated PROMININ-1 (D).
Open arrow shows syntenin-1 co-immunoprecipitated with PROMININ-1
(E). The amount of syntenin-1 and ezrin associated with PROMININ-1 was
quantified (F). Aliquots corresponding to 500 (A–C, E) and 1,250 (D) ml of
saliva were loaded. Molecular mass markers (kDa) are indicated.
doi:10.1371/journal.pone.0098927.g008
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chial epithelial cells seems to use this pathway [52,84]. Yet, it
cannot be excluded that both mechanisms occur simultaneously
[28,81]. The presence of PROMININ-1–negative membrane vesicles
carrying ERM proteins indicates that multiple kinds of membrane
vesicles are found in saliva. Indeed, a recent proteome of two
distinct types of membrane vesicles that are classified according to
their size and DPPIV (CD26) activity has shown that PROMININ-1
could be associated with both [23].
Within these extracellular membrane vesicles, we found that
PROMININ-1 co-immunoprecipitates syntenin-1, a PDZ (PSD95/
Dlg1/ZO-1) domain-containing scaffolding protein. Syntenin-1
interacts and controls the intracellular trafficking of a wide range
of plasma membrane proteins [85] including those associated with
tetraspanin-enriched microdomain [86], and is therefore directly
or indirectly implicated in multiple physiological and pathological
cellular processes. Together with syndecan and ALIX, syntenin-1
also regulates the biogenesis of exosomes [87], which is consistent
with the release of PROMININ-1 in association with these vesicles.
The ubiquitination of numerous proteins found in saliva-derived
PROMININ-1–containing membrane vesicles and PROMININ-1 itself
(Fig. 8B, C) are also in line with the presence of ubiquitinated
proteins in exosomes as reported earlier for those found in human
urine [88]. The nature, the location in relation with cellular
trafficking and the significance of the interaction of PROMININ-1
with syntenin-1 need to be further determined, but the existence of
various PROMININ-1 splice variants harboring distinct cytoplasmic
C-terminal domains with alternative classes of PDZ-binding motif
is interesting in the context of the modular and flexible recognition
of PDZ domain-containing protein partner(s) [89]. Yet, in light of
recent publications demonstrating the interaction of syntenin-1
with ubiquitin [90,91], we could not exclude that syntenin-1 may
somehow bind to the ubiquitin molecules linked to PROMININ-1.
Such interaction might regulate the sorting of ubiquitinated
PROMININ-1 into multi-vesicular bodies en route to exosomes. The
isolation of a large PROMININ-1–containing protein complexes
including syntenin-1 and CD63 needs also to be considered
[24,92], and the proteome of the immunoprecipitate will provide
further insights. Given the growing body of publications suggesting
a role for PROMININ-1 and syntenin-1 in cancer progression and
metastasis their interaction under normal and pathological
conditions deserves particular attention in a near future. It is
worth mentioning in support of the present finding that both
molecules were found in the proteomic profile of a sub-population
of EpCAM-associated exosomes that are released from LIM1863
colon carcinoma cell-derived organoids [93].
In conclusion, the immunohistochemical profile of PROMININ-1
in human salivary glands reveals its general expression at the
apical plasma membrane of the epithelial cells of intercalated ducts
in normal glands, tumors and in inflammatory diseases such as SA.
Biochemically, the ubiquitination of PROMININ-1 and its interaction
with syntenin-1 highlight new features of its intra- and intercellular
trafficking. Considering the link between stem cell differentiation
and the loss of PROMININ-1 via asymmetric cell division and/or its
release in association with membrane vesicles [16,21,28,94], new
perspectives in the biology of stem and cancer stem cells might emerge.
Supporting Information
Figure S1 Lack of PROMININ-1 in specific regions of
pleomorphic adenoma, acinic cell and mucoepidermoid
carcinomas. PA (A–C), AciCC (D, E) and MEC (F–K) samples
were labeled with 80B258 mAb directed against PROMININ-1 prior
to hematoxylin counterstaining. Boxed areas (A1, B1, C1, D1, E1,
E2) are displayed at higher magnification. In PA, mesenchymal-
like components (i.e. chondroid, myxochondroid and hyalinized
areas) are negative (A-C, respectively). In AciCC with solid growth
pattern, black and white arrows indicate the lack PROMININ-1 in the
acinar (D1, E1) and non-specific glandular (E2) cells, respectively.
CT, connective tissue. In MEC, white, blue and black arrows
indicate intermediate (F), squamous (G, H) and clear (I–K) cells,
respectively. Histopathological characteristics of individual cases of
PA: #5 (A), #3 (B) and #4 (C), AciCC: #2 (D) and #9 (E), and
MEC: #14 (F), #6 (G, H), #9 (I–K) are summarized in Table S1.
Scale bars 50 mm.
(TIF)
Figure S2 PROMININ-1 is partially co-expressed with CEA
and MUC1 in acinic cell carcinoma. Consecutive sections of
three individual cases of AciCC (A–D, see Table S1 for the
histopathological characteristics) were immunolabeled for PROMI-
NIN-1 (80B258 mAb), CEA (Parlam 4) and MUC1 (115D8 or DF3)
or with isotype control (ctrl) prior to hematoxylin counterstaining.
Boxed areas (B1, C1) are displayed at higher magnification. Black
arrowheads indicate partial (A, D) or complete (B1, C1) co-
expression of analyzed antigens at the apical membrane of cells in
the cyst-like structures present in the periphery of tumors (C, C1)
or its individual nodules (A, B) and/or in the vicinity to
hemorrhagic areas (C, C1, red asterisk). CT, connective tissue.
Scale bars 50 mm.
(TIF)
Figure S3 PROMININ-1 is co-expressed with either CEA or
MUC1 or both in adenoid cystic carcinoma. Consecutive
sections of three individual cases of AdCC (A–F, see Table S1 for
histopathological characteristics) were immunolabeled for PROMI-
NIN-1 (80B258 mAb), CEA (Parlam 4) and MUC1 (115D8 or DF3)
or with isotype control (ctrl) prior to hematoxylin counterstaining.
Boxed areas (C1) are displayed at higher magnification. Black
arrowheads indicate the complete or partial co-expression of
analyzed antigens in the duct-like structures that include the
secretion (A) and the apical membrane of cells lining ducts (B, E,
F). Blue arrowheads indicate immunoreactivities within the
cytoplasm and/or entire plasma membrane of cells in solid tumor
structures (B–D) present in the vicinity to the hemorrhagic areas
(red asterisk). Red arrowheads show single tumor cells close to
erythrocytes (C1). Note that the MUC1 detection by means of
DF3 mAb is often weaker (C, D) or negative (E). Scale bars 50 mm.
(TIF)
Figure S4 PROMININ-1 is partially co-expressed with CEA
and MUC1 in pleomorphic adenoma, non-neoplastic
peritumoral salivary gland regions and glands affected
by sialadenitis. Consecutive sections of PA (A–C), MEC (D)
and SA (E, F) individual cases (see Table S1 for histopathological
characteristics) were immunolabeled using 80B258, Parlam 4 and
115D8/DF3 mAbs directed against PROMININ-1, CEA and MUC1,
respectively, or with isotype control (A–F, ctrl) prior to
hematoxylin counterstaining. Two distinct areas of PA (A, B),
peritumoral regions (C, D) and SA (E, F) are depicted. Dashed
lines demarcate the tumor (T) from the surrounding non-
neoplastic areas (blue asterisk). Black arrowheads indicate
immunoreactivities at the apical membrane of cells lining either
ductal structures of PA or intercalated ducts in both non-neoplastic
peritumoral tissues (C, D) and SA (E, F). Note that DF3 antibody
gives a weaker or negative signal in non-cancerous tissues. Scale
bars 50 mm.
(TIF)
Figure S5 MUC1, but not PROMININ-1 and CEA, is
frequently expressed in mucoepidermoid carcinoma.
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Consecutive sections of individual cases of MEC as indicated (A–F,
see Table S1 for histopathological characteristics) were immuno-
labeled for PROMININ-1 (80B258 mAb), CEA (Parlam 4) and
MUC1 (115D8 or DF3) or with isotype control (ctrl) prior to
hematoxylin counterstaining. Orange arrowhead (A) points to
PROMININ-1 in well-differentiated tumor mucous cells present in
hemorrhagic region (red asterisk). MUC1 appears in squamous (C,
D, blue arrow), intermediate (C, white arrow), clear (E, black
arrow) and anaplastic (F, red arrow) tumor cells. MUC1 is found
on the whole cell membrane or in cytoplasm (white and black
arrowhead, respectively). Green arrowhead indicates CEA (F).
Scale bars 50 mm.
(TIF)
Table S1 Histopathological characteristics of individual
cases.
(DOC)
Table S2 Specification of primary antibodies.
(DOC)
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